BioCentury | Apr 6, 2018
Clinical News

EC approves rare disease drug from Chiesi

...form of human alpha mannosidase. The company gained the product through its 2013 acquisition of Zymenex A/S...
BioCentury | Apr 4, 2018
Company News

Chiesi drug scores approval for rare disease

...form of human alpha mannosidase. The company gained the product through its 2013 acquisition of Zymenex A/S. Allison...
BioCentury | Feb 2, 2018
Clinical News

CHMP backs approval of Chiesi's Lamzede for alpha-mannosidosis

...The company gained the recombinant form of human alpha mannosidase through its 2013 acquisition of Zymenex A/S...
BioCentury | Jan 26, 2018
Company News

CHMP backs Hemlibra, Shingrix, Lamzede

...The company gained the recombinant form of human alpha mannosidase through its 2013 acquisition of Zymenex A/S...
...Santhera added CHF0.65 to CHF28.95 on Friday. Jaime De Leon ACE910 emicizumab-kxwh GSK1437173A Hemlibra HZ/su idebenone Raxone RG6013 RO5534262 Shingrix SNT-MC17 Chiesi Farmaceutici S.p.A. Genentech Inc. GlaxoSmithKline plc Santhera Pharmaceuticals Holding AG Zymenex A/S Roche Factor...
BioCentury | Sep 8, 2014
Finance

Chiesi expands rare disease universe

...acquired U.S. rare disease partner Cornerstone Therapeutics Inc. Last year, Chiesi acquired rare disease company Zymenex A/S...
BioCentury | Sep 2, 2013
Company News

Chiesi, Zymenex deal

...Chiesi will acquire Zymenex for an undisclosed amount. Chiesi will gain Zymenex's Lamazym (rhLaman), a recombinant...
...to provide details, and Zymenex could not be reached. Chiesi Farmaceutici S.p.A. , Parma, Italy Zymenex A/S...
BioCentury | Aug 27, 2013
Company News

Chiesi to acquire rare disease company Zymenex

...will acquire rare disease company Zymenex A/S (Hillerod, Denmark) for an undisclosed amount. Chiesi will gain Zymenex's...
...standalone rare disease unit in Europe and the U.S. Back Bay Life Science Advisors advised Zymenex. BC...
BioCentury | May 20, 2013
Strategy

Let a thousand ideas bloom

...research milestones; $72M in milestones for each candidate selected; royalties Aug-09 Zymenex A/S Product acquisition Acquires Zymenex's...
BioCentury | Jan 7, 2013
Clinical News

Lamazym: Phase II data

...Lamazym also non-significantly improved FVC by 9.2% compared to baseline (p=0.157). Based on the data, Zymenex...
...Phase III trial to evaluate once-weekly 1 mg/kg IV Lamazym in 25 patients with alpha-mannosidosis. Zymenex...
...24, 2011). Lamazym has Orphan Drug designation in the U.S. and Europe for the indication. Zymenex A/S...
BioCentury | Jan 2, 2012
Clinical News

Galaczym regulatory update

...FDA granted Orphan Drug designation for Galaczym from Zymenex's Ace Biosciences A/S subsidiary to treat globoid...
...for the indication. Galaczym also has Orphan Drug designation for the indication in the EU. Zymenex A/S...
Items per page:
1 - 10 of 23
BioCentury | Apr 6, 2018
Clinical News

EC approves rare disease drug from Chiesi

...form of human alpha mannosidase. The company gained the product through its 2013 acquisition of Zymenex A/S...
BioCentury | Apr 4, 2018
Company News

Chiesi drug scores approval for rare disease

...form of human alpha mannosidase. The company gained the product through its 2013 acquisition of Zymenex A/S. Allison...
BioCentury | Feb 2, 2018
Clinical News

CHMP backs approval of Chiesi's Lamzede for alpha-mannosidosis

...The company gained the recombinant form of human alpha mannosidase through its 2013 acquisition of Zymenex A/S...
BioCentury | Jan 26, 2018
Company News

CHMP backs Hemlibra, Shingrix, Lamzede

...The company gained the recombinant form of human alpha mannosidase through its 2013 acquisition of Zymenex A/S...
...Santhera added CHF0.65 to CHF28.95 on Friday. Jaime De Leon ACE910 emicizumab-kxwh GSK1437173A Hemlibra HZ/su idebenone Raxone RG6013 RO5534262 Shingrix SNT-MC17 Chiesi Farmaceutici S.p.A. Genentech Inc. GlaxoSmithKline plc Santhera Pharmaceuticals Holding AG Zymenex A/S Roche Factor...
BioCentury | Sep 8, 2014
Finance

Chiesi expands rare disease universe

...acquired U.S. rare disease partner Cornerstone Therapeutics Inc. Last year, Chiesi acquired rare disease company Zymenex A/S...
BioCentury | Sep 2, 2013
Company News

Chiesi, Zymenex deal

...Chiesi will acquire Zymenex for an undisclosed amount. Chiesi will gain Zymenex's Lamazym (rhLaman), a recombinant...
...to provide details, and Zymenex could not be reached. Chiesi Farmaceutici S.p.A. , Parma, Italy Zymenex A/S...
BioCentury | Aug 27, 2013
Company News

Chiesi to acquire rare disease company Zymenex

...will acquire rare disease company Zymenex A/S (Hillerod, Denmark) for an undisclosed amount. Chiesi will gain Zymenex's...
...standalone rare disease unit in Europe and the U.S. Back Bay Life Science Advisors advised Zymenex. BC...
BioCentury | May 20, 2013
Strategy

Let a thousand ideas bloom

...research milestones; $72M in milestones for each candidate selected; royalties Aug-09 Zymenex A/S Product acquisition Acquires Zymenex's...
BioCentury | Jan 7, 2013
Clinical News

Lamazym: Phase II data

...Lamazym also non-significantly improved FVC by 9.2% compared to baseline (p=0.157). Based on the data, Zymenex...
...Phase III trial to evaluate once-weekly 1 mg/kg IV Lamazym in 25 patients with alpha-mannosidosis. Zymenex...
...24, 2011). Lamazym has Orphan Drug designation in the U.S. and Europe for the indication. Zymenex A/S...
BioCentury | Jan 2, 2012
Clinical News

Galaczym regulatory update

...FDA granted Orphan Drug designation for Galaczym from Zymenex's Ace Biosciences A/S subsidiary to treat globoid...
...for the indication. Galaczym also has Orphan Drug designation for the indication in the EU. Zymenex A/S...
Items per page:
1 - 10 of 23